TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Treatment discontinuations caused by GI AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of dyspeptic-type GI AEs
Endpoint domain: Adverse events/effects
Primary endpoint: percent of index segments with < 50% stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Grade 3/4 Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: excellent clinical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neurological lesions
Endpoint domain: Adverse events/effects
Primary endpoint: procedure time
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: ACR50 at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean DAS28-CRP at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sj(O(2)) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sc(O(2)) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Haemoglobin (Hb) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Immune response to vaccines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cold and hot pain thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cold sensation thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phosphorylation of mammalian target of rapamycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phosphorylation of p70-S6 kinase 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: H.pylori eradication rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to C(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight loss of at least 5% at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enjoyment of sexual activity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Discomfort during sexual activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PIPP scores during heel pricks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical episode duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of itching
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: duration until symptom free
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Methamphetamine-positive urine test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation of smoking sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of oxygen therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Asthma clinical severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change in cIMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Framingham score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Symptomatic relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pain and anxiety reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: insulin-stimulated glucose oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: NFL thickness in the unaffected quadrant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Center of Pressure (COP) forward shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forward stability limits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erroneous expectations regarding pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Erroneous expectations regarding postoperative motor outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Erroneous expectations regarding timing of postoperative recovery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean bone width after 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Upper limb dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of pain resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in mean VAS values to cold air
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in mean subjects' self‐perceived VAS values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-op sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: marginal stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of hip fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Occurrence of upper arm fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: asthma symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Specificity of NF cytology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the receiver operating characteristic curve (AUC) for NF cytology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of life of AYA
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: high-sensitivity C-reactive protein (hsCRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: apolipoprotein B (Apo B)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pancreatic cancer risk
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of involuntary movements
Endpoint domain: Adverse events/effects
Primary endpoint: NAG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: uCr levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: TP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Obtaining all measures with rolling 12-month reporting periods
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in frailty risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in EQ-VAS score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in Barthel Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: condition-specific quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean heart rate decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of symptomatic bradycardia
Endpoint domain: Adverse events/effects
Primary endpoint: cognitive decline measured by 3MS points
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: speech ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cost per quality-adjusted life-year
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: sensory or motor block levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of spinal block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postanesthetic side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Conversion percentage of cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Conversion percentage of sitosterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of obstetric complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trauma due to shoulder dystocia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Invasive treatment for severe postpartum haemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of COPD admissions
Endpoint domain: Mortality/survival
Primary endpoint: Mean duration of COPD admissions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SGRQ scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: global DNA methylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of Dot-ELISA test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Specificity of Dot-ELISA test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Dyspnea Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Quality-adjusted life-year (QALY)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevention of skeletal-related events (SREs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to re-exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dyspnea improvement (MMRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Health-related quality of life (CAT)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Postoperative pulmonary complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Length of time of hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Improvement of mean test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virginity reported
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge of birth control method efficacy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Self-efficacy to refuse sex
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adherence to guidelines for anticoagulant therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median number of attacks per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of treatment courses without attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with a decrease in attacks of greater than 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new statin prescriptions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average peak gentamicin concentration in ALF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ALF/serum penetration ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health quality improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Correction of myopic astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and severity of cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Duration of cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency of post-treatment exit visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mMRC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean efficiency of neural respiratory drive during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diaphragmatic EMG at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of CNV in the fellow eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to normal activity duration
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean levels of vancomycin in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean levels of vancomycin in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phrenic nerve injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Loss of 3 or more lines of visual acuity (VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe visual decline (6 lines or more)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity of less than 0.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FOB use for verification of final position of the tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Need for FOB to correct the dislodgement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximal movement-evoked pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postprandial incremental glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: area under the incremental glucose curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of syphilis infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HDRS-17 outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of sphincter of Oddi manometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication adherence greater than 90%
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Chocolate intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total filtered QRS duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of post-myocardial infarction angina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduced hearing
Endpoint domain: Adverse events/effects
Primary endpoint: Reduced vision
Endpoint domain: Adverse events/effects
Primary endpoint: Prediction of banana intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: catheter loss attributable to luminal thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: Pain intensity difference (PID)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum of pain relief (TOTPAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GLOBAL evaluation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Norepinephrine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pain tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Taste pleasantness score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mortality levels
Endpoint domain: Mortality/survival
Primary endpoint: Cost per child visit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Latency time to the onset of the peribulbar block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total number of drinks consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum total cholesterol (T-Chol) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Low-density lipoprotein cholesterol (LDL-Chol) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intake of total vegetables and fruits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibre intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasminogen activator inhibitor-1 activity (PAI-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Thrombin-antithrombin complexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: High-sensitivity C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean reduction in Ramu's score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline in BI (Bacteriological Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major in-hospital event risk
Endpoint domain: Mortality/survival
Primary endpoint: five-year cardiac mortality
Endpoint domain: Mortality/survival
Primary endpoint: autoregulatory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving ASAS 20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of bacteremia at 30 seconds
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary monocyte chemoattractant protein-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Duration of AF before re-establishment of sinus rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative white blood cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall success rate
Endpoint domain: Mortality/survival
Primary endpoint: Infection scores
Endpoint domain: Adverse events/effects
Primary endpoint: Continuous abstinence at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Point-prevalence rates of smoking cessation at 3, 6, and 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 50% or greater reduction in daily cigarette consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tapering off immunosuppressive medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total ulcer healing scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in tissue type
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change in HAQ DI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: circulating DKK‐1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bone mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KT‐1000‐measured knee laxity in external rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: VAS for satisfaction with surgery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: atherogenic cardiovascular risk markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: tumor absorbed dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor-to-healthy-tissue uptake ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viremia levels in patients with genotype 1b vs genotype 2a
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Readmission ascertainment sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Readmission ascertainment specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life years (QALY's) gained
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Average annual healthcare costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain score (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Peak value of troponin-t post-PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Morphine dose
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Self-reported subjective state
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Physical state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: performance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Functional connectivity of brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes